ISSN 3105-6741(Print)
ISSN 3105-675X(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3105-6741(Print)
ISSN 3105-675X(Online)

CODEN:LYYAA3
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社(CAS)
DOI前缀:
https://doi.org/10.66106/lyyaa3

WorldCat(世界图书馆目录)

OCLC 编号:11198178435

国图集团 CIBTC
进口备案刊号:G015Z125

索引 / 检索 / 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。

CNKI(中国知网,申请中)
CNKI Open(中国知网·开放平台,申请中)
CQVIP(维普期刊网,中国)
CQVIP(中文期刊服务平台,中国)
RCCSE(中国学术期刊目录,武汉大学)
CJWK(长江文库,中国)
BOOKAN(博看,中国)
591adb(中邮阅读·万章期刊,中国)
Baidu Scholar(百度学术,中国)
Baidu Baike(百度百科,中国)
ICI(哥白尼期刊数据库,波兰)
EuroPub(欧洲学术出版数据库,英国)
MDPI scilit(科学与学术数据库,瑞士)
Crossref(交叉引用,美国)
Semantic Scholar(语义学术,美国)
OpenAlex(全球开源学术平台,加拿大)
ACADEMIA.EDU(学术界,美国)
OUCI(开放乌克兰科学,乌克兰)
WorldCat(世界编目数据库,美国)
Scite(智能引文分析数据库,美国)
The Lens(透镜学术,澳大利亚)
OpenAIRE(开放学术发现门户,欧洲)
Google Scholar(谷歌学术,美国)
DOI(数字对象唯一标识符,英国)
Portico(数字存储库,美国)
J-Gate(开放获取期刊门户,印度)
ResearchGate(研究之门,德国)
Research Commons(科睿唯安,美国)
ADL(亚洲数字图书馆,巴基斯坦)
Socolar(开放获取资源检索,中国,更新中)
Sci Online(科学在线,中国澳门)
OALib(开放存取资源图书馆,美国)
EZB(电子期刊图书馆,德国,申请中)
Road(开放科学学术资源,法国)
ISI(国际科学索引平台,阿联酋迪拜)
ASCI(亚洲科学引文索引,美国)
ESJI(欧亚科学期刊索引,哈萨克斯坦)
ResearchBib(研究者索引,日本)
SPI-Hub™(范德比尔特大学,美国)
SJIF(科学期刊影响因子,印度)
RJIF(研究期刊影响因子)
COSMOS(期刊评价指标,印度)
LivRe!(开放期刊门户,巴西)
KIND CONGRESS(阿塞拜疆)
Journament(质量评估与索引)
IP Indexing(ip索引)
Magzter(跨平台数字期刊,美国)
SlideShare(知识共享平台,美国)
SCRIBD(在线图书馆,美国)
Yahoo! Search(雅虎,美国)
Microsoft Bing(微软学术,美国)
LibKey(学术文献快捷获取工具)
R Discovery(研究者发现平台,印度)

Enterscholar(恩特学术,中国)

Scholay(Scholay学术,中国)

Minicod(学术数据 API,法国)

DiscountMags(折扣杂志,美国伊利诺伊)

Rootindexing(根索引,印度)

Synapse(突触,美国)

POSI(全景开放学术索引,中国香港)

GUL(乔治城大学图书馆,美国)

规划申请
Scopus 爱思唯尔·斯高帕斯(荷兰)

SinoMed 中国生物医学文献服务系统

DOAJ 开放获取期刊目录(瑞典)

PubMed 医学文摘数据库(美国)

PubMed Central 医学全文数据(美国)

EMBASE 爱思唯尔·医学文摘(荷兰)

EBSCO 学术文献数据库(美国)

OAJ 全球OA期刊索引(中国)

CABI 国际农业与生物科学中心(英国)

ProQuest 科睿唯安(美国)

Research4Life 世界卫生组织数据库

武汉办事处
主任 库盛娟
电话 +86 027-8860 7188
邮箱 gjqk@qikan999.com
微信 qikan7188
地址 武汉市武昌东湖路181号
邮编 430077
Editing and Publishing
Macau Sino-Foreign Medical Publishing Limited(MSFMP)
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://lcyyyj.scionline2025.com

  往期阅览 · All Issues-> 2026年 · 2026  
临床用药研究,2026年,第2卷,第3期,第22-25页,pISSN 3105-6741、eISSN 3105-675X 发布者:Quest Press 发布日期:2026/11/2
Open Access 浏览140次

 

参松养心胶囊联合常规西医治疗气阴两虚络脉瘀阻型心悸的临床疗效及安全性观察


王凤娟

河南中医药大学第五临床医学院(郑州人民医院),河南郑州,450003

摘要:目的:观察参松养心胶囊联合常规西医基础方案治疗气阴两虚、心络瘀阻型心悸患者的临床疗效与用药安全性,量化对比两组不良反应发生情况。方法:选取2024年12月—2026年2月本院心内科收治的心悸患者82例,采用随机数字表法分为对照组、观察组各41例。对照组实施常规心血管基础治疗+生活方式干预;观察组在对照组方案基础上加用参松养心胶囊口服,连续干预8周。对比两组治疗前后心悸发作频率、单次发作持续时间、中医证候积分、24h动态心电图早搏负荷;统计两组临床总有效率,分项记录并对比各类不良反应发生率。结果:治疗前两组各项观察指标无统计学差异(P>0.05);治疗8周后,两组心悸症状、中医证候、心律失常负荷均较治疗前改善,且观察组心悸发作频次、持续时间、证候积分下降幅度、早搏负荷改善程度均优于对照组(P<0.05)。不良反应方面,观察组总不良反应发生率7.32%,对照组总发生率21.95%,观察组胃肠道不适、头晕、皮肤过敏发生率均显著低于对照组(P<0.05),无严重不良事件。结论:参松养心胶囊联合常规西医治疗可显著改善气阴两虚络脉瘀阻型心悸患者临床症状,减少心律失常发作,整体用药安全性更高,适合临床推广应用。

关健词:参松养心胶囊;心悸;心律失常;气阴两虚;心络瘀阻;不良反应;中西医结合
Clinical Efficacy and Safety Observation of Shensong Yangxin Capsule Combined with Conventional Western Medicine in the Treatment of Palpitations of Qi-Yin Deficiency and Collateral Stasis Pattern

Fengjuan Wang

The Fifth Clinical Medical College of Henan University of Chinese Medicine(Zhengzhou People’s Hospital),Zhengzhou, 450003,China

Abstract:Objective:To observe the clinical efficacy and medication safety of Shensong Yangxin Capsule combined with conventional basic western medicine regimen in the treatment of patients with palpitations of Qi-Yin deficiency and heart collateral stasis pattern,and to quantitatively compare the incidence of adverse reactions between the two groups.Methods:A total of 82 patients with palpitations admitted to the Department of Cardiology of our hospital from December 2024 to February 2026 were enrolled and divided into a control group and an observation group via random number table method,with 41 cases in each group. The control group received conventional basic cardiovascular therapy combined with lifestyle intervention;on the basis of the treatment for the control group,the observation group was additionally given oral Shensong Yangxin Capsule for continuous intervention of 8 weeks. The frequency of palpitations,duration of single attack,TCM syndrome scores and premature beat load on 24-hour ambulatory electrocardiogram before and after treatment were compared between the two groups. The overall clinical effective rate was calculated,and the incidence of various adverse reactions was recorded item by item and compared.Results:There were no statistically significant differences in all observation indicators between the two groups before treatment (P>0.05). After 8 weeks of treatment,palpitations,TCM syndromes and arrhythmia load in both groups were improved compared with those before treatment. Moreover,the reduction amplitude of palpitations attack frequency,attack duration,syndrome scores,and the improvement degree of premature beat load in the observation group were superior to those in the control group (P<0.05). In terms of adverse reactions,the total incidence rate of adverse reactions was 7.32% in the observation group versus 21.95% in the control group. The incidence rates of gastrointestinal discomfort,dizziness and skin allergy in the observation group were significantly lower than those in the control group (P<0.05),and no serious adverse events occurred.Conclusion:Combination therapy of Shensong Yangxin Capsule and conventional western medicine can significantly relieve clinical symptoms and reduce arrhythmia attacks in patients with palpitations of Qi-Yin deficiency and collateral stasis pattern,with higher overall medication safety,which is worthy of clinical promotion and application.


Keywords : Shensong Yangxin Capsule;Palpitations;Arrhythmia;Qi-Yin Deficiency;Heart Collateral Stasis;Adverse Reactions;Integrated Traditional Chinese and Western Medicine


参考文献
[1] 李红蓉.基于络病理论从气血相关角度论治心律失常[J]. 南京中医药大学学报,2024,40 (10):1245-1251.
[2] 闫卫红,李玉峰,鲁卫星,等.参松养心胶囊治疗心血不足心络瘀阻型心悸伴室性早搏临床疗效观察 [J]. 现代中医临床,2007,14(4):23-26.
[3] 高宇,袁勇,李润琴.参松养心胶囊治疗阵发性房颤疗效及对患者血清 CK、CK-MB、cTnI 水平的影响 [J]. 中华中医药学刊,2026,44 (2):31-33.
[4] 《中成药治疗冠心病临床应用指南(2020 年)》编写组.中成药治疗冠心病临床应用指南 (2020 年)[J]. 中国中西医结合杂志,2021,41(1):1-10.
[5] 丁征,张艳华,陈佳.参松养心胶囊致 INR 值降低 2 例及文献回顾 [J]. 中国现代应用药学,2018,35(11):1368-1371.
[6] 孙凯丽.参松养心胶囊联合西药治疗室性早搏 (气阴两虚证) 的疗效及对心率变异性的临床观察 [J]. 现代医学研究,2026(5):62-66.
[7] 通络药物系统干预心血管事件链专家共识专家组.通络药物系统干预心血管事件链专家共识 [J]. 中西医结合心脑血管病杂志,2025,23(3):321-328.
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/。
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Macau Sino-Foreign Medical Publishing Ltd.(MSFMP)
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The MSFMP publishes articles under the following open access license.
Quest Press
is a member of the following organizations.